Consulting, Advisory & MedComms

With a senior partner network accumulating more than 250 years of combined experience and a C-level relationship portfolio cultivated over two decades, Aagami, Inc. operates as a high-access consultancy for life sciences organisations seeking to expand across borders. Headquartered in Naperville, Illinois, the firm has completed more than 200 assignments for over 110 clients spanning pharmaceuticals, biotechnology, medical devices and technology, consumer healthcare, CROs, CDMOs, and academia. The core value proposition is bandwidth extension: Aagami supplements a client's in-house capability where geography, language, or resource constraints limit reach. Its four principal service lines are strategic consulting , technology licensing, business research and market intelligence, and business development support. A key differentiator is the firm's deep understanding of business and socio-cultural differences across global markets, enabling clients to navigate regulatory environments, commercial customs, and stakeholder expectations that vary significantly by region. Clients engaging Aagami typically seek access to decision-makers that are difficult to approach through internal channels. The firm's approach centres on leveraging long-standing executive relationships and cross-sector experience to reduce the time, effort, and cost involved in international business development and technology licensing transactions. Its newsletter and publications programme, including the long-running Pullan's Pieces series, reflects the firm's commitment to sharing market intelligence with the broader life sciences community. Further information is available at aagami.com.

Adelphi Communications brings together real-world evidence, HEOR data, clinical evidence, and patient-reported outcomes into a unified, insight-led approach designed to optimise patient outcomes across the healthcare industry. The agency operates as a global medical communications partner, with offices in the UK and USA, and forms part of the wider Adelphi Group network of specialist healthcare consultancies. Capabilities and Approach At the core of Adelphi Communications' model is a highly collaborative way of working, grounded in knowledge and integrity. The agency's team draws from backgrounds in scientific and medical research, enabling it to develop creative, evidence-informed solutions to the complex challenges facing pharmaceutical and healthcare clients. Its work spans five principal disciplines, including scientific publications, congress support, digital medical education, and strategic medical communications planning. The agency's distinctive methodology lies in how it synthesises multiple data sources. By combining real-world evidence and HEOR data with clinical evidence and patient-reported outcomes, Adelphi Communications equips clients with a cohesive roadmap rather than fragmented analysis from isolated data streams. This evidence synthesis approach is particularly suited to healthcare companies navigating complex regulatory, market access, and clinical evidence environments. Adelphi Communications recruits across its UK and USA offices, offering professionals an environment with intensive on-the-job coaching and a structured programme of targeted training, making it a recognised employer within the medical communications sector. Further information is available at adelphicommunications.com.

Part of the 100% family-owned Tiefenbacher Group, AET provides end-to-end pharmaceutical development and out-licensing solutions spanning more than 80 countries. With over 900 employees and its own laboratories and manufacturing facilities, the group builds efficient supply chains for marketing partners across every major regulated market, removing the full burden of development risk from commercial partners and accelerating their time-to-market. Out-Licensing Model and Core Capabilities AET's business model centres on developing, manufacturing, and registering pharmaceutical products before licensing them to partners worldwide. The portfolio covers value-added generic drug development , innovative medicines, and high-potent compounds, addressing three strategic pillars: better affordability, broader global availability, and genuine therapeutic improvement. From early formulation through regulatory dossier preparation, clinical supply, and multi-market registration, AET manages the entire product life cycle on behalf of its licensing partners. A recognised strength is the organisation's expertise in preparing best-in-class regulatory dossiers that support complex simultaneous launches across multiple jurisdictions. This capability has attracted some of the world's most trusted pharmaceutical brands as long-term partners, underpinned by consistent manufacturing quality and a scalable supply-chain infrastructure that handles both small-molecule and high-potency product categories. The Tiefenbacher Group's integrated model, combining in-house R&D, production, and regulatory affairs under one ownership structure, offers partners a single point of accountability from concept to commercial launch. AET's reach across diverse regulatory environments, from the European Medicines Agency to emerging-market agencies, makes it a capable partner for companies seeking to extend the commercial footprint of established or novel pharmaceutical products. Further information is available at aet.eu.

With a consulting network of more than 350 specialists spanning research and development and commercial functions, Alacrita Life Science Consulting provides strategic guidance and hands-on execution to biotech and pharmaceutical companies navigating drug development. The firm serves a broad client base that includes virtual and semi-virtual biotechs, established pharmaceutical companies, investors, technology transfer offices, and animal health companies. Alacrita's product development services span the full programme lifecycle, from opportunity mapping and preclinical strategy through clinical development, regulatory affairs, and CMC consulting. On the commercial side, the firm supports business planning, fundraising, interim chief medical officer engagements, and virtual biotech operations. Technology platform strategy, launch planning, and business development round out a service offering designed to cover the stages where specialist input most often determines programme outcomes. The firm also provides enterprise development services including due diligence, valuations, in-licensing and asset scouting, out-licensing, partnering and deal-making, and academic commercialisation. An investor services practice and expert witness capability further extend the scope available to clients. Alacrita's coverage extends across a wide range of product modalities, including antibodies and ADCs, cell therapies, gene therapies, radiopharmaceuticals, peptides and proteins, small molecules, and microbiome drugs. Disease area expertise encompasses oncology, CNS, immunology, haematology, respiratory, endocrine and metabolic conditions, fibrosis, and digestive and gastrointestinal disease, among others. Further information is available at alacrita.com.